Premium
YOUNG HIGH RISK PATIENTS WITH DIFFUSE LARGE B‐CELL LYMPHOMA INCLUDING BCL‐2/MYC DOUBLE HIT LYMPHOMAS BENEFIT FROM DOSE‐DENSE IMMUNOCHEMOTHERAPY WITH EARLY CNS PROPHYLAXIS
Author(s) -
Leppä S.,
Jørgensen J.,
Tierens A.,
Meriranta L.,
Østlie I.,
Brown P.,
Fagerli U.,
Larsen T.S.,
Mannisto S.,
Munksgaard L.,
Maisenhølder M.,
Vasala K.,
Meyer P.,
Jerkeman M.,
Björkholm M.,
Fluge Ø.,
Jyrkkiö S.,
Ralfkiaer E.,
Spetalen S.,
KarjalainenLindsberg M.,
Holte H.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.92_2629
Subject(s) - medicine , international prognostic index , vincristine , diffuse large b cell lymphoma , rituximab , lymphoma , gastroenterology , cytarabine , cyclophosphamide , etoposide , prednisone , chop , surgery , oncology , chemotherapy